Sodium channel blockers for skin disorders

Abstract

Provided are methods of treating a variety of disorders of the skin with inhibitors of the epithelial sodium channel (ENaC). The inhibitors are represented by formula (I)-(IV): where R is defined herein.

1 . A method of treating a disorder of the skin in a human in need thereof comprising administering to the human an effective amount of a compound represented by formula (I)-(IV): 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         2 . The method of  claim 1 , wherein the disorder of the skin is psoriasis. 
     
     
         3 . The method of  claim 1 , wherein the disorder of the skin is an inflammatory disease of the skin. 
     
     
         4 . The method of  claim 1 , wherein the disorder of the skin is a wound. 
     
     
         5 . The method of  claim 1 , wherein the disorder of the skin is a lesion or ulcer of the skin. 
     
     
         6 . The method of  claim 1 , wherein the disorder of the skin is eczema. 
     
     
         7 . The method of  claim 1 , wherein the disorder of the skin is lupus. 
     
     
         8 . The method of  claim 1 , wherein the disorder of the skin is rosacea. 
     
     
         9 . The method of  claim 1 , wherein the disorder of the skin is a skin rash. 
     
     
         10 . The method of  claim 1 , wherein the disorder of the skin is a cold sore, shingles or acne. 
     
     
         11 . The method of  claim 1 , wherein the compound represented by formula (I)-(IV) is administered topically. 
     
     
         12 . The method of  claim 1 , wherein the compound represented by formula (I)-(IV) is a pharmaceutically acceptable salt. 
     
     
         13 . A method of minimizing scarring in a human in need thereof comprising administering to the human an effective amount of a compound represented by formula (I)-(IV): 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         14 . The method of  claim 13 , wherein the compound represented by formula (I)-(IV) is administered topically. 
     
     
         15 . The method of  claim 13 , wherein the compound represented by formula (I)-(IV) is a pharmaceutically acceptable salt.